Prometheus Biosciences, Inc. (RXDX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Mark C. McKenna.
RXDX tiene fecha de IPO 2021-03-12, 97 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $9.56B.
Prometheus Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and companion diagnostics for inflammatory bowel diseases (IBD). The company's lead candidate, PRA023, is a humanized monoclonal antibody currently in Phase IIa clinical trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Prometheus maintains a robust pipeline including multiple therapeutic programs targeting different disease mechanisms in IBD and immune-mediated conditions, supported by strategic partnerships with leading pharmaceutical companies including Takeda, Dr. Falk Pharma, and Millennium Pharmaceuticals. Headquartered in San Diego, California, the company was incorporated in 2016 and formerly operated under the name Precision IBD, Inc. before rebranding to Prometheus Biosciences in October 2019.
